anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A health care system includes a management server to which a user of a diabetic patient or the like accesses via the internet from a user terminal such as a personal computer and so on. The management server provides to the user terminal interview checklists of four categories including emotion, motivation, depression and stress in repose to the access. The user performs an input of answers on the interview checklist according to a conducting procedure. The management server processes the input of the answers and stores a processing result in a database. Accordingly, the user can know an evaluation (interview result) determined by the management server by accessing the database. It is noted that in the management server, interviews are performed at appropriate timings according to priorities of respective categories of the interview lists so as to prevent the interview lists of all the categories from being performed on the same day.
Background and Objectives: The global rise in obesity presents a significant public health challenge, with Turkey exhibiting one of the highest obesity rates in Europe. Body image dissatisfaction (BID) and lower food literacy (FL) have been associated with obesity, yet their interplay remains underexplored. This study aimed to investigate the relationship between body mass index (BMI), body image dissatisfaction, and FL in adults in Turkey. Materials and Methods: In total, 759 women and 419 men aged 18-64 years old were included in this study. The mean age was 31.34 ± 11.92. A total of 1178 participants completed an online questionnaire assessing anthropometric measurements, BID, using the Stunkard Figure Rating Scale, and FL, using a validated questionnaire. The data were analyzed using descriptive statistics, correlation analysis, and mediation analysis to explore the relationships between variables in SPSS 24.0. Results: Women desired to be thinner more frequently than men, and those with negative BID were predominantly individuals with overweight or obesity. Moreover, those with higher FL scores were more likely to be satisfied with their bodies. Correlation analysis demonstrated a negative relationship between BMI and FL (r = -0.94; p = 0.001) and a positive relationship between BMI and BID (r = 0.628; p < 0.001). Mediation analysis revealed that FL mediated the relationship between BID and BMI (β = -2.281; lower limit = -3.334, upper limit = -1.228). Conclusions: The findings highlight the importance of addressing BID and enhancing FL to mitigate obesity risk factors. This study contributes to understanding the complex interplay between BID, FL, and obesity, providing insights for public health interventions aimed at obesity prevention and management.
A universal folding method that has been demonstrated to be effective in refolding a variety of very different pro-teins expressed in bacteria as inclusion bodies has been developed. Representative proteins that can be dissolved and refolded in biologically active form, with the native structure, are shown in Table I. The method has two key steps to unfold and then refold the proteins expressed in the inclusion bodies. The first step is to raise the pH of the protein solution in the presence of denaturing agents to pH greater than 9, preferably 10. The protein solution may be maintained at the elevated pH for a period of up to about 24 hours, or the pH immediately decreased slowly, in increments of about 0.2 pH units/24 hours, until the solution reaches a pH of about 8.0, or both steps used. In the preferred embodiment, purified inclusion bodies are dissolved in 8 M urea, 0.1 M Tris, 1 mM glycine, 1 mH EDTA, 10 mM beta-mercaptoethanol, 10 mM dithiothreitol (DTT), 1 mM redued glutathion (GSH), 0.1 mM oxidized glutathion (GSSG), pH 10. The absorbance at 280 nm (OD280) of the protein solution is 5.0. This solution is rapidly diluted into 20 volumes of 20 mM Tris base. The resulting solution is adjusted to pH 9.0 with 1 M HCl and is kept at 4 C for 24 hrs. The pH is adjusted to pH 8.8 and the solution is kept at 4 C for another 24 hrs. This process is repeated until the pH is adjusted to 8.0. After 24 hrs at pH8.0, the refolded proteins can be concentrated by ultrafiltration and applied to a gel filtration column for purification.
BACKGROUND: Obesity is an important health problem worldwide. The prevalence of obesity in Aotearoa New Zealand (AoNZ) is the third highest amongst OECD countries. Previous studies have demonstrated inequity in the provision of bariatric and metabolic surgery (BMS) across AoNZ, but detailed data regarding patients and surgical outcomes is lacking. The aim of this study is to examine the rates and outcomes of BMS between patients domiciled in a metropolitan versus provincial area in AoNZ.
METHODS: A 5-year retrospective observational cohort study of all patients who received BMS domiciled in a metropolitan or a provincial area in the Northern region of AoNZ was performed. Interrogation of patient electronic medical records and clinical notes was performed to collect the required baseline characteristics, secondary outcome measure data and confirm domicile.
RESULTS: The rate of BMS was 6.1 times higher in the population with class III obesity domiciled in the metropolitan versus the provincial population. Patients in the metropolitan area were less obese, had lower rates of diabetes and had a wider range of procedures performed. Māori were underrepresented in both cohorts. There was a higher resolution of diabetes in the provincial patients.
CONCLUSION: This study has highlighted significant differences in the rate, type and outcomes of BMS between a metropolitan and provincial area in the Northern region of AoNZ. This represents a significant health inequity. Changes in national and regional policies are needed to ensure equitable care for patients with obesity in AoNZ.
The invention relates to micromolecule polypeptide preventing and restraining inflammation and application of the micromolecule polypeptide. The invention further relates to the preparation method of the micromolecule polypeptide and a medicine composition containing the polypeptide. The micromolecule polypeptide preventing and restraining inflammation has a plurality of advantages, such as the molecular weight is small. The micromolecule polypeptide preventing and restraining inflammation can penetrate through various kinds of ocular tissue protective screens. The micromolecule polypeptide preventing and restraining inflammation and the application is good in water solubility. The high concentration can be maintained in neutral tear liquid, aqueous fluid and a vitreous body. The micromolecule polypeptide preventing and restraining inflammation and the application of the micromolecule polypeptide have the advantages of being simple in composition, low in prepared cost and the like.
The present invention is directed to cellulytic host cells. The host cells of the invention expressing heterologous cellulases and are able to produce ethanol from cellulose. According to the invention, host cells expressing a combination of heterologous cellulases can be used to produce ethanol from cellulose. In addition, multiple host cells expressing different heterologous cellulases can be co-cultured together and used to produce ethanol from cellulose. Furthermore, the invention demonstrates for the first time the ability of  Kluveryomyces  to produce ethanol from cellulose. The yeast strains and co-cultures of yeast strains of the invention can be used to produce ethanol on their own, or can also be used in combination with externally added cellulases to increase the efficiency of saccharification and fermentation processes.
Local pain or burning, and rectal bleeding attributed to Hydrocortisone Rectal Suspension, USP have been reported rarely. Apparent exacerbations or sensitivity reactions also occur rarely. The following adverse reactions should be kept in mind whenever corticosteroids are given by rectal administration. 

Fluid and Electrolyte Disturbances: Sodium retention; fluid retention; congestive heart failure in susceptible patients; potassium loss; hypokalemic alkalosis; hypertension. Musculoskeletal: Muscle weakness; steroid myopathy; loss of muscle mass; osteoporosis; vertebral compression fractures; asceptic necrosis of femoral and humeral heads; pathologic fracture of long bones. Gastrointestinal: Peptic ulcer with possible perforation and hemorrhage; pancreatitis; abdominal distention; ulcerative esophagitis. Dermatologic: impaired wound healing; thin fragile skin; petechiae and ecchymoses; facial erythema; increased sweating; may suppress reactions to skin tests. Neurological: Convulsions; increased intracranial pressure with papilledema (pseudo-tumor cerebri) usually after treatment; vertigo; headache. Endocrine: Menstrual irregularities; development of Cushingoid state; suppression of growth in pediatric patients; secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery or illness, decreased carbohydrate tolerance; manifestations of latent diabetes requirements for insulin or oral hypoglycemic agents in diabetics. Ophthalmic: Posterior subcapsular cataracts; increased intraocular pressure; glaucoma; exophthalmos. Metabolic: Negative nitrogen balance due to protein catabolism.
ADT protocol is administered as a single subcutaneous injection of 3-month depot of 22.5 mg of leuprolide acetate (luteinizing hormone-releasing hormone \[LHRH\] agonist). ADT protocol starts one month prior to the scheduled HIFU session. The intervention of the study is HIFU hemi-ablation combined with ADT.
The invention relates to a medicine for treating endometriosis, especially to a traditional Chinese medicine which is prepared from plant Chinese herbal medicines used as raw materials and is used for treating endometriosis. According to the technical scheme, raw medicinal materials comprise 2-10 g of ginger, 2-10 g of ligusticum wallichii, 5-15 g of Chinese angelica, 5-15 g of radix paeoniae rubrathe, 5-15 g of cattail pollen, 5-15 g of flying squirrel feces, 2-10 g of peach kernel, 2-10 g of red sage root, 2-10 g of curcuma rhizome, 2-10 g of sparganium, 2-10 g of spina gleditsiae, 5-15 g of myrrh and 2-10 g of rhizoma cyperi. With compatibility of the above medicines, the medicines complement each other. The traditional Chinese medicine has effects of activating blood circulation to dissipate stasis, clearing away heat and toxic materials, dispersing blood stasis, relieving pain, cooling the blood and diminishing swelling, eliminating vexation, soothing the nerves, moistening the intestines, relaxing bowel and the like. By oral administration of the traditional Chinese medicine, internal order is adjusted, the healthy energy is supported, endocrine disorder is regulated, body immune function is enhanced, yin and yang are balanced, dynamic equilibrium of functions of internal organs is recovered, and treatment of endometriosis is effectively achieved. The traditional Chinese medicine has no side effect, is economical and can be made by oneself.
Retinitis pigmentosa (RP) is a collective term for a group of inherited retinal dystrophies that are a major cause of irreversible blindness. RP of some type occurs in approximately 1 out of 3500 persons in the United States. Gene mutations are responsible for the majority of RP. To date, mutations have been identified in 30 different genes linked to RP. The visual prognosis of RP is poor, since the gradual but relentless visual field loss leads eventually to some degree of blindness. Although no effective treatment for RP has been identified, participants supplemented with a daily oral dose of 15,000 IU vitamin A palmitate have shown, on average, a slower rate of deterioration of retinal function when the intervention is continued over several years. The purpose of this research is to determine whether administration of high oral doses of vitamin A can acutely improve cone photoreceptor function in RP participants as measured by electroretinography (ERG). In this interventional, non-randomized, prospective, pilot study, 10 participants (five with the RHO1 gene mutation and five without the mutation) will receive a daily oral dose of 50,000 IU of vitamin A palmitate for 4 weeks, followed by a maintenance dose of 15,000 IU daily for the subsequent 2 weeks. The primary efficacy outcome is a relative percentage change in ERG response amplitude subsequent to vitamin A supplementation. A secondary efficacy outcome is a relative percentage change in implicit time from pre- to post- vitamin A supplementation, with improvement specified as a shorter response implicit time. Other secondary outcomes will be improvements in visual field (Humphrey 10-2; sum of thresholds). Safety outcomes include visual fields, ETDRS visual acuity, intraocular pressure, serum vitamin A level and liver function tests.
A method and apparatus are provided for treating biological cellular material with a treating agent using pulsed electrical fields provided by a waveform generator (12). The treatment method includes obtaining an electrode assembly which includes three or more parallel rows of individual electrodes (19). The electrode assembly is applied to a treatment area. Electrically conductive pathways are established between the electrodes (19) and the waveform generator (12) through an array switch (14). Successive electric fields are applied to the treatment area in the form of successive electric field waveforms from the waveform generator (12), through the array switch (14), to adjacent rows of electrodes (19), wherein each successive electric field has the same direction, and wherein polarities of rows of electrodes are reversed successively during the applying of the successive electric fields between adjacent successive rows of electrodes to the treatment area. As a result, the biological cellular material in the treatment area is treated with the treating agent unidirectionally with uniform electric fields with a minimization of the formation of deleterious electrochemistry products at the electrodes.
We present the case of a 52-year-old woman with a history of HBeAg-negative chronic hepatitis B virus (HBV) infection, viral load (VL) Z+<20,000U.l/ml with no evidence of liver fibrosis and, therefore, untreated. She presented to the emergency department with jaundice, epigastric pain, nausea, and vomiting. On admission, blood analysis revealed ALT 3982U/l, AST 3221U/l, Gamma-GT 80U/l, alkaline phosphatase 252U/l, LDH 960U/l, bilirrubin12.5mg/dl; no elevation of acute phase reactants, 141,000 platelets and coagulopathy with a prothrombin activity of 29%. Abdominal ultrasound showed no relevant findings. The serological profile revealed AgHBs+, anti-HBe+ y anti-HBc IgM+ and VL VHB>100 mills. Ul/ml, the remaining serology was negative and other causes of liver disease were ruled out. With the diagnosis of severe acute hepatitis (SAH) due to HBV reactivation (HBVR) treatment with entecavir was initiated. Given the analytical evolution (Table 1) and the appearance of encephalopathy grade I-II/IV, an urgent liver transplant was performed. The histological result of the explant was conclusive with intense interphase and lobular hepatitis with extensive areas of massive necrosis in both lobes, without hepatic fibrosis compatible with fulminant hepatitis (FH).
AIMS: The incidence of obesity increases annually. It is closely related to the occurrence of cardiovascular diseases, malignant tumors, etc., and has become a major global health problem. 5-hydroxytryptamine (5-HT), a multifunctional monoamine neurotransmitter, is dispersed throughout the central nervous system and digestive tract. It is intimately related to the mechanism of obesity.
MATERIALS AND METHODS: PubMed, Web of Science and Embase were carefully searched. We collected articles that are closely related to 5-HT, the gut-brain axis, and obesity.
KEY FINGDINGS: The gut microbiota not only influences nutrient metabolism but also centrally meditates appetite and mood regulation. The gut-brain axis, a system connecting the gut and the brain, is known to participate in two-way communication between the gut flora and the central nervous system.
SIGNIFICANCE: There have been few reports on whether peripheral and central 5-HT interact bidirectionally via the gut-brain axis and jointly play a role in the pathogenesis of obesity. In this review, we summarize the rationale for the contribution of the 5-HT-related gut-brain axis to the development of obesity and explore feasible signaling pathways, which elucidates new targets for preventing and treating obesity.
Doxorubicin (DOX) is a widely utilized chemotherapeutic agent in clinical oncology for treating various cancers. However, its clinical use is constrained by its significant side effects. Among these, the development of cardiomyopathy, characterized by cardiac remodeling and eventual heart failure, stands as a major concern following DOX chemotherapy. In our current investigation, we have showcased the efficacy of MLN4924 in mitigating doxorubicin-induced cardiotoxicity through direct inhibition of the NEDD8-activating enzyme, NAE. MLN4924 demonstrated the ability to stabilize mitochondrial function post-doxorubicin treatment, diminish cardiomyocyte apoptosis, alleviate oxidative stress-induced damage in the myocardium, enhance cardiac contractile function, mitigate cardiac fibrosis, and impede cardiac remodeling associated with heart failure. At the mechanistic level, MLN4924 intervened in the neddylation process by inhibiting the NEDD8 activating enzyme, NAE, within the murine cardiac tissue subsequent to doxorubicin treatment. This intervention resulted in the suppression of NEDD8 protein expression, reduction in neddylation activity, and consequential manifestation of cardioprotective effects. Collectively, our findings posit MLN4924 as a potential therapeutic avenue for mitigating doxorubicin-induced cardiotoxicity by attenuating heightened neddylation activity through NAE inhibition, thereby offering a viable and promising treatment modality for afflicted patients.
BACKGROUND: The Energy-Adjusted Dietary Inflammatory Index (E-DII) is related to both body mass index (BMI) and hyperuricemia. However, the association among BMI, hyperuricemia and DII is yet to be fully elucidated. The purpose of this study is to explore the role of BMI in the relationship between E-DII and hyperuricemia in the American population.
METHODS: A cross-sectional study was conducted using data from the National Health and Nutrition Examination Survey (NHANES) spanning from 2007 to 2016, with a sample size of 10,571 participants. The study used a weighted logistic regression model and a generalized additive model (GAM) to explore the associations among BMI, hyperuricemia and E-DII. Furthermore, mediation analysis was utilized to illustrate the mediating relationships among these variables.
RESULTS: The results of the study indicated that a higher E-DII was related to an increased risk of hyperuricemia. The association between E-DII and hyperuricemia was partially mediated by BMI.
CONCLUSIONS: E-DII is associated with hyperuricemia. BMI mediates the relationship between E-DII and hyperuricemia among Americans, which provides crucial information for the prevention of hyperuricemia.
This study investigated the role of O-GlcNAc cycling in Alzheimer's disease-related changes in brain pathophysiology induced by chronic REM sleep deprivation (CSD) in mice. CSD increased amyloid beta (Aβ) and p-Tau accumulation and impaired learning and memory (L/M) function. CSD decreased dendritic length and spine density. CSD also increased the intensity of postsynaptic density protein-95 (PSD-95) staining. All of these Alzheimer's disease (AD) pathogenic changes were effectively reversed through glucosamine (GlcN) treatment by enhancing O-GlcNAcylation. Interestingly, the lelvel of O-GlcNAcylated-Tau (O-Tau) exhibited an opposite trend compared to p-Tau, as it was elevated by CSD and suppressed by GlcN treatment. CSD increased neuroinflammation, as indicated by elevated levels of glial fibrillary acidic protein and IBA-1-positive glial cells in the brain, which were suppressed by GlcN treatment. CSD promoted the phosphorylation of GSK3β and led to an upregulation in the expression of endoplasmic reticulum (ER) stress regulatory proteins and genes. These alterations were effectively suppressed by GlcN treatment. Minocycline not only suppressed neuroinflammation induced by CSD, but it also rescued the decrease in O-GlcNAc levels caused by CSD. Minocycline also reduced AD neuropathy without affecting CSD-induced ER stress. Notably, overexpressing O-GlcNAc transferase in the dentate gyrus region of the mouse brain rescued CSD-induced cognitive dysfunction, neuropathy, neuroinflammation, and ER stress responses. Collectively, our findings reveal that dysregulation of O-GlcNAc cycling underlies CSD-induced AD pathology and demonstrate that restoration of OGlcNAcylation protects against CSD-induced neurodegeneration.
Patients receive topotecan IV over 30 minutes on days 1-5. Beginning with course 2, patients also receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
The disclosed technology describes compositions and methods useful for providing cell based therapy. For example, one embodiment of cell based therapy involves the regeneration of injured tissue and/or promoting wound healing. Certain embodiments provide improved therapeutic compositions using microbubbles by delivering biological progenitor cells to the injured tissues. The administration of the microbubbles is directed by acoustic radiation forces that interact with embodiments of microbubbles comprising an acoustically active gas. As such, a high efficiency of progenitor cell delivery to injured tissue is realized. One advantage of this technique over targeted delivery of pharmaceutical compounds, is that the delivered progenitors cells may be derived from the patient (i.e., personalized therapy), thereby avoiding side effects, allergic reactions, and overall problems associated with refractive drug responses.
Patients will receive oral doses of PCI-32765 in Cohort 1, Cohort 2 and CLL/SLL Cohort. In Cohort 1, single oral dose of PCI-32765 140 mg and 280 mg will be given before administration of daily oral doses of 420 mg per day for 35 days in Cycle 1 and for 28 days in Cycle 2 and thereafter. In Cohort 2 and CLL/SLL Cohort, PCI-32765 560 mg and 420 mg per day, respectively will be administered daily for 35 days in Cycle 1 and for 28 days in Cycle 2 and thereafter.
Participants with metastatic non-small cell lung cancer (NSCLC) with Kirsten rat sarcoma (KRAS) p.G12C mutation whose tumors express \< 1% programmed death-ligand 1 (PD-L1) and/or serine/threonine kinase 11 (STK11) mutation in need of first line treatment will be administered sotorasib 240 mg daily. Participants will be stratified by known presence of STK11 mutation.